尼妥珠单抗联合三维适形放化疗治疗食管癌的初步研究  

A pilot study for the effect of nimotuzumab combined with 3D- CRT and chemoradiotherapy on esophagus cancer

作　　者：伍楚蓉[1] 杨文[1] 唐武兵[1] 潘兴喜[1] 卢奕宇[1] 张永胜[1] 陈永发[1] 梁海春[1] 

机构地区：[1]南方医科大学附属南海医院肿瘤1科,广东佛山528200

出　　处：《现代肿瘤医学》2014年第12期2842-2845,共4页Journal of Modern Oncology

摘　　要：目的:探讨尼妥珠单抗联合放化疗治疗食管癌的疗效及不良反应。方法:经组织病理确诊的食管癌初诊患者60例分为两组,对照组(n=30)采用三维适形放疗及周期化疗;观察组(n=30)除三维适形放疗及周期化疗外,每周放疗前进行尼妥珠单抗100mg治疗,共6-7次。结果:放疗结束后2个月复查完全缓解率(CR),观察组为76.7%,对照组为66.7%,两组有效率(RR)均为100.0%。随访2年对照组和观察组的局部区域控制率为86.7%和93.3%(P>0.05),无远处转移生存率分别为70.0%和76.7%(P>0.05),两组间CR率及复发转移率比较均无统计学差异(P>0.05)。两组主要不良反应为放射性食管黏膜炎、放射性皮炎和恶心呕吐反应、粒细胞减少、疲乏等,无皮疹及过敏反应发生,不良反应均为患者所耐受,观察组发生Ⅱ级以上放射性食管黏膜炎、粒细胞减少较对照组偏高,但差异无统计学意义(P>0.05)。结论:尼妥珠单抗可提高食管癌对放疗的敏感性,提高有效率、降低复发转移率,安全有效。Objective： To study the effect and adverse reaction of nimotuzumab combined with 3D- CRT and chemoradiotherapy on esophagus cancer. Methods： Total of 60 esophagus cancer patients after preliminary diagnosis by tissue pathology examination were divided into two group,the control group（ n = 30） who received 3D conformal therapy and period chemotherapy,and the observation group（ n = 30） received 100 mg nimotuzumab administration before3 D conformal therapy and period chemotherapy. All patients received 6 to 7 times of treatment. Results： 2 months after radiotherapy,the complete remission rate（ CR） of observation group was 76. 7% while that of control group was 66. 7%. And the effective rates（ RR） were both 100. 0%. The local region control rates after 2- year＇s follow-up visit were 86. 7% for control group and 93. 3% for observation group,respectively（ P 0. 05）,while the non-metastasis survival rates were 70. 0% and 76. 7%（ P 0. 05）. The adverse reactions reported from the both group included radioactive esophageal mucosal inflammation,radioactive dermatities and nausea and vomiting,granulocytopenia,fatigue,but neither erythra nor allergy was recorded. Despite that the rates of class- Ⅱ radioactive esophageal mucosal inflammation and granulocytopenia in observation group was higher than that of control group（ without significant difference,P 0. 05）,the patients tolerated the above adverse reaction. Conclusion： Nimotuzumab could enhance the esophagus cancer patients＇ sensitivity to radiotherapy,increase its efficacy,and decrease recurrence as well as metastasis,indicating nimotuzumab would be a safe and effective agent for esophagus cancer.

关 键 词：食管癌 尼妥珠单抗 放化疗法 单克隆抗体 

分 类 号：R730.5[医药卫生—肿瘤] R735.1[医药卫生—临床医学]